Results 201 to 210 of about 513,616 (274)

Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Transition from long‐term denosumab (Dmab) to parathyroid hormone‐analogs or romosozumab (Romo) might expose patients to the risk of the so‐called rebound phenomenon. Adding Romo to Dmab might represent an option in patients experiencing a fracture while on Dmab.
Giovanni Adami   +10 more
wiley   +1 more source

Integrative single cell RNA‐sequencing and spatial transcriptomics uncovers distinct macrophage‐fibroblast cross‐talk in human hip synovium between patients with femoroacetabular impingement and osteoarthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives Femoroacetabular impingement (FAI) and synovitis have been recognized as essential factors for developing osteoarthritis (OA) in the hip joints. However, little is known about altered synovial cellular compositions, their associated transcriptomic profiles, and cell‐cell interactions in FAI and hip OA.
Gulzada Kulzhanova   +9 more
wiley   +1 more source

Population pharmacokinetics and dose–response relationships of mitoxantrone in children with acute myeloid leukaemia

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Background Information on mitoxantrone pharmacokinetics in children is lacking and reduced dosing regimens applied to infants are supported by limited scientific rationale. The current study characterized mitoxantrone pharmacokinetics in a childhood acute myeloid leukaemia patient population and provides a data‐informed assessment of dosing.
Andrew M. Brandon   +13 more
wiley   +1 more source

A critical guideline for controlling monocyte-derived macrophages phenotypes. [PDF]

open access: yesFront Immunol
Moschetti G   +7 more
europepmc   +1 more source

Calcium retinoate nanoparticle mediated microglial polarization to regulate inflammatory microenvironment for therapy of neuroinflammatory disease

open access: yesBMEMat, EarlyView.
A nano‐drug based on retinoic acid and calcium is developed, which can be rapily endocytosed by microglia and decomposed into small molecule/ion storms in lysosomes. This nano‐drug regulates microglial phenotype switching from M1 to M2 while indirectly guiding neuronal differentiation of endogenous neural stem cells, thereby ameliorating ...
Shuo Zhang   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy